
7 mentions across press, blogs, and newsletters
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxNY0xqMWd2eGliaDNJN092RVEwZF9tN1hhUzFtZ0NScnhMYm92ZW1KSHBMN24zbkUwaXdPLThBNEp4WjR1NFRyRmhvWGpQYmZfRXNVWWlLYTZGTFFkTkhOaEZrQWVHUm1SYnFuSTN2ZndVdElqakRTc3VxOWd5Vk1tcHBzaHNOVjdLRVlVOFpKSFhPUzROVHlKUWxpcjdBTzlXOTNkNkRSdGxDUzQzclkzeExPZ3dfVEpOcm
US pharmaceutical giant Eli Lilly is betting big on AI-driven
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxQRUtWbXlUNS04X1dualdiUTg0ME11ajdLb3FGekwyT1lXbFhmT2ltNUVUUVFna1RQYmh6OUJRcWd5bk1ETXE0LUNWbVRRU0NQUFFYaWk4bXlwX3EwX1lSTW1WWHFsV2c3R0ZpT1p6S29fMDlBdzhtRy1VY1VoV1hDaGg3UnJzNDlkSGVTeE5HckNCUmxBNUZxN3dhRm1FT2ltaE43UDVQUUMtQTZIdkRPV1dreGVXOEljME
Lilly will acquire exclusive rights to sell a GLP-1 drug for diabetes from Insilico Medicine, the FT report said, citing sources familiar with the matter.
Hong Kong-listed Insilico Medicine has signed a cooperation agreement with the United Arab Emirates’ drug regulator to advance the use of its artificial intelligence tools in drug discovery across the region, even as geopolitical tensions escalate in the Middle East. Shares of Insilico rose as much